Researchers reviewed data from 872 ulcerative colitis patients and Crohn’s disease patients from the UC and CD Victory Consortium database to compare safety between the two therapies. Patients were matched 1 to 1.
Here’s what you should know:
1. Entyvio patients had lower surgical infection and serious adverse event rates compared to the patients on a biologic monotherapy.
2. Among patients on a biologic therapy featuring a combination of steroids and immunomodulators, infection and adverse event rates were similar between Entyvio and TNFα-antagonist treated patients
3. Concomitant immunosuppressive use put both patient groups at increased risk for infections and adverse effects.
Victory Consortium analyses lead investigator Parambir Dulai, MD, said, “As we add to the extensive body of real-world evidence supporting the safety profile of Entyvio, it is encouraging to see the lower rates of serious infections and adverse events as compared to TNFα-antagonist therapy in this rigorous analysis. Further studies will seek to understand the potential impact of gut-selective treatment versus systemic immunosuppression on clinical safety in the real world.”
More articles on gastroenterology:
How an Oregon-based ASC combats decreasing case volume
All hands on deck: Pinnacle III VP’s 10 strategies for building ASC teamwork
ASGE raising awareness of esophageal adenocarcinoma — 3 insights
